Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Allakos ( (ALLK) ) has provided an announcement.
On May 15, 2025, Allakos Inc. completed a merger with Concentra Biosciences, LLC, following a successful tender offer by Concentra’s subsidiary to acquire all outstanding shares of Allakos at $0.33 per share. As part of the merger, Allakos’s shares were delisted from Nasdaq, and the company became a wholly owned subsidiary of Concentra, leading to changes in its corporate structure and reporting obligations.
The most recent analyst rating on (ALLK) stock is a Hold with a $0.30 price target. To see the full list of analyst forecasts on Allakos stock, see the ALLK Stock Forecast page.
Spark’s Take on ALLK Stock
According to Spark, TipRanks’ AI Analyst, ALLK is a Underperform.
Allakos faces significant financial challenges with no revenue and ongoing cash burn, exacerbated by recent strategic setbacks like the AK006 discontinuation and layoffs. While some technical indicators show short-term positive momentum, the overall risks and negative sentiment from corporate events weigh heavily, resulting in a low stock score.
To see Spark’s full report on ALLK stock, click here.
More about Allakos
Allakos Inc. operates in the biotechnology industry, focusing on developing therapeutic solutions for allergic and inflammatory diseases.
Average Trading Volume: 1,177,821
Technical Sentiment Signal: Sell
Current Market Cap: $29.76M
Learn more about ALLK stock on TipRanks’ Stock Analysis page.